Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369918 | 0.81 | PTGDR2 (0.43) | LMNAMAPK1PTGDR2ALDH1A1POLB | |
| SCHEMBL1371402 | 0.65 | PTGDR2 (0.41) | LMNAMAPK1PTGDR2ALDH1A1POLB | |
| SCHEMBL1370144 | 0.64 | PTGDR2 (0.31) | PTGDR2 | |
| SCHEMBL12145508 | 0.61 | PTGDR2 (0.42) | PTGDR2ALDH1A1CA1CA2 | |
| SCHEMBL16126803 | 0.58 | CA1 (0.42) | LMNAMAPK1PTGDR2ALDH1A1POLB | |
| SCHEMBL19378180 | 0.58 | NPC1 (0.36) | LMNAALDH1A1POLBTSHRKMT2A | |
| SCHEMBL19378182 | 0.58 | NPC1 (0.36) | LMNAALDH1A1POLBTSHRKMT2A | |
| SCHEMBL22203929 | 0.57 | NQO2 (0.40) | LMNAMAPK1ALDH1A1POLBTSHR | |
| SCHEMBL19125887 | 0.56 | KDM1A (0.46) | POLBMEN1KMT2A | |
| SCHEMBL2509450 | 0.55 | S100A4 (0.37) | LMNAMAPK1ALDH1A1POLBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273769-B2 | Phenoxy acetic acid derivatives | MERCK SERONO SA (CH) | 2012-09-25 | — | — | US | disclosed |
| EP-2396295-A1 | PHENOXY ACETIC ACID DERIVATIVES | Merck Serono S.A. (CH) | 2011-12-21 | — | — | EP | disclosed |
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-11-24 | — | — | US | disclosed |
| WO-2010092043-A1 | PHENOXY ACETIC ACID DERIVATIVES | MERCK SERONO S.A. (CH) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288066-A1 | PHENOXY ACETIC ACID DERIVATIVES | HRH2, HRH1, HRH3 | LMNA 4243/4885MAPK1 843/4885PTGDR2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.